(Q39031210)

English

The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor

scientific article published on 4 February 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor (English)

1 reference

Europe PubMed Central

8 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Tetsuya Mitsudomi

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24458568%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24458568%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Hiroshi Mizuuchi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24458568%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Katsuaki Sato

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24458568%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Toshiki Takemoto

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24458568%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Takuya Iwasaki

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24458568%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

0 references

publication date

4 February 2014

1 reference

Europe PubMed Central

8 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24458568%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

135

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24458568%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1002-1006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24458568%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24458568%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28737

21 January 2018

Identifiers

10.1002/IJC.28737

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24458568%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24458568%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39031210&oldid=1803341639"